Therapeutic approach with mesenchymal stem cells secretome on a cell model of inflammation and fibrosis

Postgraduate Thesis uoadl:2963203 129 Read counter

Unit:
Specialty Molecular Biomedicine Mechanisms of Disease, Molecular and Cellular Therapies, and Bioinnovation
Library of the School of Health Sciences
Deposit date:
2021-10-21
Year:
2021
Author:
Giakoub Farinta
Supervisors info:
Γαζούλη Μαρία, Kαθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Μπάμιας Γεώργιος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Καραμανώλης Γεώργιος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Therapeutic approach with mesenchymal stem cells secretome on a cell model of inflammation and fibrosis
Languages:
English
Translated title:
Therapeutic approach with mesenchymal stem cells secretome on a cell model of inflammation and fibrosis
Summary:
Idiopathic inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory diseases with a significant increase of incidence in recent years. The exact etiology of IBD remains unknown, while a large number of factors, such as the environment, immune response and genetic predisposition, contribute to the pathogenesis of these diseases. The epidemiological data suggests that westernised lifestyle is the reason of increased incidence of IBD and provides evidence of the role that the environment plays in the appearance of these diseases. Therapeutic practice that is usually used is the gradual use of immunosuppressive and anti-inflammatory agents which are followed by the use of biological agents such as anti-TNF-α. Existing treatments, apart from the failure to eliminate the need for surgery, provoke significant side-effects, some of which are very serious and can endanger patients’ life if there is no proper monitoring. For this reason, it is imperative to search for new therapies.
Seeking more effective and safer treatments targeting various sources of human stem cells and their conditioned medium are being studied as forms of treatment for inflammation related diseases such as IBD. Human amniotic fluid- mesenchymal stem cells conditioned medium have already used in the laboratory for the treatment of an IBD in mice model using chemical induced colitis. Evaluation of anti-inflammatory procedure was realized by histopathological observation of the colonic tissue and immunohistochemical methods with really encourage results.
In the present series of experiments human intestinal subepithelial myofibroblasts which are shown to be implicated in intestinal inflammation and fibrosis were isolated by patient with Crohn’s disease and were cultivated in the laboratory. Then they were treated with LPS, lipopolysaccharide, a microbial molecule used for the induction of inflammatory response, administrated with conditioned medium of hAF-MSC. In our results was observed reduction in the expression of the tested pro-inflammatory cytokines TNF-α, IL-6 and IL-8, leading to the inference that conditioned medium may have therapeutic potential and the confirmation of these result and optimization of their medical administration will indicate a new therapeutic approach for Inflammatory Bowel Diseases.
Main subject category:
Health Sciences
Keywords:
Conditioned medium, Intestinal subepithelial myofibroblasts, Inflammatory bowel disease, LPS ,Therapeutic, Intestins
Index:
No
Number of index pages:
0
Contains images:
Yes
Number of references:
48
Number of pages:
49
Giakoub Farinta Master.pdf (1 MB) Open in new window